Plaque psoriasis market is predicted to reach USD 32.7 billion at a CAGR of 8.80% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Plaque psoriasis market”.

The plaque psoriasis market is estimated to register a CAGR of 8.80% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global plaque psoriasis market— Pfizer Inc.,GlaxoSmithKline plc, Novartis AG , Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson Private Limited, Bayer AG, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company , Cadila Pharmaceuticals, Eli Lilly and Company , LEO Pharma A/S , Cipla Inc. , Aurobindo Pharma , Lupin , Sumitomo Corporation.

Market Highlights

The global plaque psoriasis market is accounted to register a CAGR of 8.80% during the forecast period and is estimated to reach USD 32.7 billion by 2032.

The market for plaque psoriasis is anticipated to develop during the forecast period due to a growing prevalence of psoriasis and a strong and promising medication pipeline. The market for plaque psoriasis is anticipated to expand as a result of the shift in lifestyle. Moreover, a rise in treatment awareness is anticipated to moderate the market expansion for plaque psoriasis. However, throughout the course of the projection period, it is anticipated that the adverse effects of current treatments.

Access full report @ https://www.marketresearchfuture.com/reports/plaque-psoriasis-market-16119

Segment Analysis

The global plaque psoriasis market has been segmented based on treatment, route of administration, end use and distribution Channel.

On the basis of treatment, the market is segmented into Topical therapy, Phototherapy, Systemic agents, Biologic therapies and others. The biologic therapies segment was attributed to holding the largest market share in 2022 due to the fact that biologic therapies are that therapies which have less side effects for human body.

Based on route of administration, the global plaque psoriasis market has been segmented into Power Oral and Injectable. The oral segment was expected to hold the largest market share in 2022 as a result of the major companies' quick research and development on these applications

On the basis of end use, the market is segmented into Hospitals, Homecare, Speciality centres and others. The hospitals segment was attributed to holding the largest market share in 2022 because hospitals usually have access to specialized medications and treatments.

On the basis of distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. The retail pharmacy segment was attributed to holding the largest market share in 2022 due to the enormous supply and sales, as indicated by the market's strong demand.

Regional Analysis

The global plaque psoriasis market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe plaque psoriasis market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The plaque psoriasis market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World plaque psoriasis market comprises of Middle East, Africa, and Latin America.

The largest market share for plaque psoriasis was maintained by the North American regional sector. The market for plaque psoriasis is dominated by North America because of the region's rising incidence of the condition. Additionally, throughout the projection period, the region's plaque psoriasis market will profit from a strong medication pipeline. The North America market for plaque psoriasis is anticipated to develop significantly because to the rise in research investment. In addition, it is anticipated that growing public awareness of the condition will fuel the region's plaque psoriasis market expansion in the upcoming years.

Moreover, the Europe market has been persistently growing over the forecast period. The demand for plaque psoriasis is driven by the growing frequency of the illness throughout Europe has significantly increased demand for therapeutic medications, driving the expansion of the regional market. As an illustration, information made public by the National Institute for Health and Care Excellence.

Additionally, Because of the increasing number of government programs to educate the public about the risks of extended psoriasis, the Asia Pacific psoriasis treatment market is expected to develop at the highest rate. For example, the Australian government recently announced that it has added two new psoriasis medications (Trampy and Lummi) to its Pharmaceutical Benefits Scheme (PBS), which would save patients up to.

Furthermore, the rest of the world's plaque psoriasis market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's rising use of strong medication pipeline. Government support, a rise in investor interest, and the viability of the technology in the sector are all contributing factors to the market expansion.

Key Findings of the Study

• The global plaque psoriasis market is expected to reach USD 32.7 billion by 2032, at a CAGR of 8.80% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the increasing number of government programs to educate the public about the risks of extended psoriasis.


• Based on end use, the hospitals segment was attributed to holding the largest market share in 2022.


• Pfizer Inc.,GlaxoSmithKline plc, Novartis AG , Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson Private Limited, Bayer AG, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company , Cadila Pharmaceuticals, Eli Lilly and Company , LEO Pharma A/S , Cipla Inc. , Aurobindo Pharma , Lupin , Sumitomo Corporation.